Evidence map›Paper›PMID 41264321›Full record

ArticleThe FEBS journal2026

Moderate increase of MET in hepatocytes protects against cholestatic liver injury by promoting an effective antioxidant response.

Carlos González-Corralejo, Juan García-Sáez, María Figueroa-Fuentes, Annalisa Addante, Cesáreo Roncero, Nerea Lazcanoiturburu, Beatriz Pacheco, Julián Sanz, Cristina Gato, Eva Fernández-Calderón and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The FEBS journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Carlos González-CorralejoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Juan García-SáezDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
María Figueroa-FuentesDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Annalisa AddanteDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Cesáreo RonceroDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Nerea LazcanoiturburuDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Beatriz PachecoDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Julián SanzAnatomical Pathology Service of the "Clínica Universidad de Navarra", Madrid, Spain.
Cristina GatoAnatomical Pathology Service of the "Clínica Universidad de Navarra", Madrid, Spain.
Eva Fernández-CalderónDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
María de la O LópezDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Águeda González-RodríguezSols Morreale Biomedical Research Institute, Spanish National Research Council and Autonomous University of Madrid (IIBM, CSIC-UAM), Spain.
Almudena PorrasDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.
Flavio MainaAix Marseille Univ, Inserm, CNRS, 'Centre de Recherche en Cancérologie de Marseille' (CRCM), Institut Paoli-Calmettes, Turing Center for Living Systems, France.
Isabel FabregatTGF-β and Cancer Group, Oncobell Program, Bellvitge Biomedical Research Institute (IDIBELL), Barcelona, Spain.
Blanca HerreraDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.ORCID 0000-0002-2415-2055
Aránzazu SánchezDepartment of Biochemistry and Molecular Biology, Faculty of Pharmacy, Complutense University of Madrid (UCM), Spain.ORCID 0000-0001-9145-6633

Funding

CIBEREHD, Instituto de Salud Carlos IIIComunidad de Madrid and co-funded by European Social Fund: Youth Employment Initiative (YEI) PEJ-2021-TL/BMD-21632FP7-People: Marie Curie Actions PITN-GA-2012-316549Ministry of Science, Innovation and Universities, Spanish Agency of Research, and co-funded by European Regional Development Fund (ERDF) PID2021-124830OB-100Ministry of Science, Innovation and Universities, Spanish Agency of Research, and co-funded by European Regional Development Fund (ERDF) RTI2018-099098-B-100NextGenerationEU Ct19/23-invm-67Universidad Complutense de Madrid (UCM) and Banco Santander CT58/21-CT59/21
6 · The paper itself

Abstract

Hepatocyte growth factor (HGF)/hepatocyte growth factor receptor (MET) signaling plays a critical role during liver regeneration upon acute and chronic damage, and is therefore an interesting target for therapeutic intervention. Nevertheless, the molecular mechanisms underlying the pro-regenerative effects of HGF/MET signaling are not fully elucidated, particularly during cholestatic injury. Our aim was to analyze the impact of moderately enhanced MET on the hepatic response to cholestatic injury, and uncover the mechanisms behind it. For that, Alb-R26

Indexed as

AntioxidantsCholestasisHepatocytesProto-Oncogene Proteins c-metAnimalsApoptosisCell ProliferationDicarbethoxydihydrocollidineDisease Models, AnimalHepatocyte Growth FactorHumansLiverLiver RegenerationMaleMiceMice, Inbred C57BL3,5-diethoxycarbonyl-1,4-dihydrocollidineAntioxidantsDicarbethoxydihydrocollidineHepatocyte Growth FactorNF-E2-Related Factor 2Proto-Oncogene Proteins c-metPyridinescholestasisglutathioneliver regenerationMetoxidative stress

Identifiers

PMID41264321
PMCPMC13080231

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.